Shanghai Fosun Pharmaceutical : PROGRESS UPDATE ANNOUNCEMENT REGARDING MEDIA REPORTS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

PROGRESS UPDATE ANNOUNCEMENT REGARDING MEDIA REPORTS

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'', together with its subsidiaries, the ''Group'') on a voluntary basis.

References are made to the relevant announcements of the Company dated 15 March, 11 November, 16 December 2020, 25 January, 25 February and 24 March 2021 (the ''Announcements'') in relation to, among others, the License Agreement regarding BioNTech's mRNA-based vaccine and certain media reports in respect thereof. Unless the context specified otherwise, capitalised terms used herein shall have the same meaning ascribed to them in the Announcements.

PROGRESS UPDATE OF THE INVESTIGATION

As at the date of this announcement, based on the investigation initiated by BioNTech against the deviations of the primary packaging materials for vials of the Vaccine products from batch ''210102'', BioNTech has confirmed that the root cause of such deviations is a combination of the primary packaging of the Vaccine and shipment under ultra-low temperature conditions, and there is no impact on the safety and efficacy of the Vaccine.

As indicated by the tests and measurement results, when the products are stored and shipped under the ultra-low temperature conditions (i.e. -70 degrees Celsius), if the container closure integrity is not maintained, it may lead to intrusion of ambient gas; and after which, during the thawing process, the flexibility of the stopper is regained and the stopper reseals the vial, which may lead to an increased pressure in the vial, and occasionally cause over pressurized vials or vial leakage. Such deviations were also identified on several cases of Vaccine products from batch ''210104'' that finished at the same site.

Through a thorough measurement and sampling, BioNTech considers that there is no evidence indicating any safety risks of the Vaccine products from batch ''210102'' and batch ''210104''; the risk of microbial contamination is minimal due to the fact that the Vaccine products are stored under ultra- low temperature conditions; despite the occurrence of the above deviations, the message RNA integrity

- 1 -

and LNP intactness in respect of the relevant batches of the Vaccine will not be affected. On the basis of the above results, BioNTech considers that the safety and the efficacy of the Vaccine are not affected by such deviations.

For the sake of prudence, the Vaccine products from batch ''210102'' and batch ''210104'' will continue to be put under quarantine before the final investigation report.

SUBSEQUENT ARRANGEMENTS

The Group and BioNTech will continue to coordinate with Hong Kong and Macau government for the vaccination programme, and the supply of the Vaccine. It is expected that another batch of the Vaccine products manufactured and finished at another site of BioNTech located in Germany will be shipped to Hong Kong recently for subsequent vaccination arrangements in Hong Kong and Macau.

Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

1 April 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

- 2 -